ArticleCancer medicine2026
Comparative Cardiovascular Safety and Exploratory Bleeding Outcomes of Ibrutinib, Acalabrutinib, and Zanubrutinib in Mantle Cell Lymphoma: A Propensity Score-Matched Real-World Analysis.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBruton tyrosine kinase inhibitors are central to the treatment of relapsed or refractory mantle cell lymphoma, but cardiovascular and bleeding toxicities influence treatment selection. Ibrutinib has been associated with atrial fibrillation/flutter and other cardiovascular adverse events, whereas second-generation covalent BTK inhibitors were developed to improve kinase selectivity and tolerability. Mantle cell lymphoma-specific real-world comparative safety data across ibrutinib, acalabrutinib, and zanubrutinib remain limited.
objectiveTo compare cardiovascular and bleeding outcomes among patients with mantle cell lymphoma treated with ibrutinib, acalabrutinib, or zanubrutinib.
methodsWe conducted a retrospective propensity score-matched TriNetX cohort study of patients with mantle cell lymphoma treated with ibrutinib, acalabrutinib, or zanubrutinib. Alternate BTK inhibitor exposure and prior recorded outcomes were excluded. Outcomes included newly recorded atrial fibrillation/flutter, heart failure, and gastrointestinal bleeding. Matching included demographics, comorbidities, cardiovascular risk factors, anthracycline exposure, and antithrombotic use.
resultsAfter matching, the 365-day cohorts included 738 patients per group for acalabrutinib versus ibrutinib, 522 per group for zanubrutinib versus ibrutinib, and 532 per group for acalabrutinib versus zanubrutinib. Newly recorded atrial fibrillation/flutter was lower with acalabrutinib than ibrutinib, 4.5% versus 12.0%, RR 0.371, HR 0.387, and with zanubrutinib than ibrutinib, 5.0% versus 12.3%, RR 0.408, HR 0.421. Atrial fibrillation/flutter rates were similar between acalabrutinib and zanubrutinib, 4.0% versus 5.7%, RR 0.704, HR 0.714. Heart failure did not differ statistically, and 180-day sensitivity analyses were consistent. Exploratory gastrointestinal bleeding was higher with ibrutinib than acalabrutinib, 4.3% versus 2.2%, and numerically higher with ibrutinib than zanubrutinib, 4.7% versus 3.3%; acalabrutinib-versus-zanubrutinib gastrointestinal bleeding output was unavailable.
conclusionsIbrutinib was associated with a higher risk of atrial fibrillation/flutter than acalabrutinib or zanubrutinib. These findings may support individualized BTK inhibitor selection, particularly among patients with baseline cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.